

## AACR Bulletin Board

**Institution of Page Charges**

Effective January 1, 1998, a page charge of \$50 per printed page will be levied on all manuscripts published in *Clinical Cancer Research*. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

**1999 Annual Meeting**

The AACR's Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Philadelphia, PA, April 10-14, 1999. The Chairperson of the Annual Meeting is Waun Ki Hong of the UT-M.D. Anderson Cancer Center. Co-Chairpersons are Carol W. Greider, Johns Hopkins University School of Medicine; Joseph F. Fraumeni, Jr., National Cancer Institute; and Leroy Fong Liu, Robert Wood Johnson Medical School.

The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, scientific forums, and meet-the-expert sunrise sessions. It will also review proffered papers submitted by members of the cancer research community and will schedule acceptable ones in minisymposia, poster discussion sessions, and poster sessions. The deadline for submission of abstracts will be **November 6, 1998**. Further program information can be found on the AACR's Website (<http://www.aacr.org>).

**Call for Nominations for 1999 AACR-Pezcoller International Award for Cancer Research**

The AACR-Pezcoller International Award for Cancer Research is given annually to a scientist who has made a major scientific discovery in the field of cancer, who continues to be active in the field, and whose ongoing work holds promise for future contributions to cancer research. The Pezcoller Foundation was established in 1982 by Professor Alessio Pezcoller, a dedicated Italian surgeon who has made important contributions to medicine during his career and who, through his foresight, vision, and generous gift in support of the formation of the Foundation, stimulated others to make significant advances in cancer research. Over the past decade the Pezcoller Foundation has given a major award for outstanding contributions to cancer and cancer-related biomedical science.

The American Association for Cancer Research (AACR) was founded in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has over 13,000 members in more than 60 countries who are experts in basic, clinical, and translational cancer research. The AACR fulfills its mission in a variety of forums, including publications, meetings, and training and educational programs. Because of the commitment of the Foundation and the AACR to scientific excellence in cancer research, these two organizations are collaborating annually on the presentation of the award. This will strengthen international collaborations and will be a catalyst for advancements in cancer research internationally. Due to the successful implementation of this joint program in 1998, the Foundation and the AACR have agreed to give this award on an annual basis.

The awardee will be selected by an international committee of AACR members appointed by the AACR President with the agreement of the Council of the Pezcoller Foundation. Although normally the Award will be presented to a single investigator, in exceptional cases two individuals may be selected to share the award when their investigations have resulted in related prizeworthy work. The committee will make its selection solely on the basis of the awardee's scientific accomplishments without regard to race, gender, nationality, or religious or political views. The candidate will give an award lecture during the AACR Annual Meeting in Philadelphia, PA, USA (April 10-14, 1999) and will receive the award in an official ceremony at the Foundation's headquarters in Trento, Italy, after the AACR Annual Meeting. The award consists of an honorarium of \$75,000 and a commemorative plaque.

The Pezcoller Foundation and the AACR are now soliciting nominations for the 1999 Award. Nominations can be made by any scientist who is now or has been affiliated with an institution engaged in cancer research. Institutions or organizations are not eligible for this award, and candidates may not nominate themselves.

**AACR**

The American Association for Cancer Research (AACR) was founded in 1907 to bring together active investigators of the cancer problem for the presentation and discussion of new findings and to foster advances in cancer research. Today the Association has over 13,000 members working in all of the subdisciplines of cancer research in the United States, Canada, and more than 60 other countries. Information on AACR programs and activities can be obtained from

American Association for  
Cancer Research  
Public Ledger Building  
150 South Independence Mall West  
Suite 826  
Philadelphia, PA 19106-3483  
Phone: (215) 440-9300  
Fax: (215) 440-9313  
E-mail: [aacr@aacr.org](mailto:aacr@aacr.org)

The AACR welcomes applications for membership from the readership. Scientists engaged in all areas of cancer research are eligible for membership. There are three categories of membership: *active* membership, open to cancer researchers working in the Americas; *corresponding* membership, to those working outside the Americas; and *associate* membership, to graduate and medical students, postdoctoral fellows, and physicians-in-training. Further information on the qualifications for each category as well as the benefits of membership can be found on the application forms at the back of this issue.

There is no official application form for this award. The nomination package should consist of the following:

- the candidate's curriculum vitae and full list of published works;
- an indication of the candidate's most important publications; and
- a letter of recommendation in English (500 words, maximum) explaining why the candidate is deserving of this prestigious Award. This letter should summarize the candidate's major scientific achievements, indicate which of the candidate's publications best describe these achievements, and explain the impact of these achievements on progress in cancer research.

Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.

The deadline for receipt of nominations by the AACR is **October 1, 1998**, for consideration for the 1999 Award. Questions about the nomination process should be directed to the AACR Office via FAX at (215) 440-9313 or E-mail at [aacr@aacr.org](mailto:aacr@aacr.org). Nominators should submit the original plus 15 copies of their nominations to: AACR-Pezcoller International Award for Cancer Research c/o American Association for Cancer Research, Inc. Public Ledger Building, Suite 826 150 South Independence Mall West Philadelphia, PA 19106-3483, USA

**Call for Nominations for AACR Awards**

The AACR presents six awards to distinguished scientists at its Annual Meeting. The Awards Committee, consisting of six separate subsections, will recommend candidates for each award to the AACR Executive Committee. Following is a description of each award. Members wishing to make nominations should provide a short description of the candidate's accomplishments; the subsection involved will obtain further documentation on suitable candidates. Nominations may be directed to the Association Office for forwarding to the appropriate subsection. This material should be received no later than **October 1, 1998**.

**Clowes Memorial Award.** The Eli Lilly Company established the Clowes Memorial Lecture to honor Dr. G. H. A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The purpose of the award is to give "recognition of outstanding research accomplished in some recent period." The Clowes Award should recognize outstanding recent accomplishments in basic cancer research, and the Board of Directors construes this to mean both laboratory research and epidemiological investigations.

**Joseph H. Burchenal AACR Clinical Research Award.** Bristol-Myers Squibb has established this award to recognize outstanding achievements in clinical cancer

research. It is named for Dr. Joseph H. Burchenal, past president and honorary member of the AACR and a leading figure in the field of cancer chemotherapy. There are no restrictions on the age or geographic location of the awardee.

**Richard and Hinda Rosenthal Foundation Award.** The Rosenthal Foundation has established this award to "recognize research which has made or gives the promise of soon making a notable contribution to improved clinical care in the field of cancer." The Foundation wishes to honor and provide incentive to young investigators relatively early in their careers. It has, therefore, stipulated that the Association restrict the award to individuals who are engaged in the practice of medicine, who reside in the Americas, and who will not be more than 50 years of age at the time of the award (April 1999).

**Rhoads Memorial Award.** In 1979, an anonymous donor established this award in memory of Dr. Cornelius P. Rhoads, a founder and the first Director of the Sloan-Kettering Institute for Cancer Research. This annual award is intended to give recognition to an "individual on the basis of meritorious achievement in cancer research." In accordance with the donor's wishes, the awardee must be a young investigator; therefore, the Board of Directors of the Association has stipulated that the recipient must not have reached his or her 41st birthday by the time of the award (April 1999).

**Cain Memorial Award.** The Warner-Lambert Company instituted this award to honor the memory of Dr. Bruce F. Cain of New Zealand for his work in the "design, synthesis, and biological evaluation of potential anticancer drugs." The purpose of the award is to "give recognition to an individual or research team for outstanding preclinical research that has implications for the improved care of cancer patients." Examples of such research include discovery of a significant new anticancer agent and major contributions to a compound's application as an antitumor agent. The award will recognize outstanding contributions in the fields of medicinal chemistry, biochemistry, or tumor biology as related to drug discovery; will encompass anticancer, antiviral, and antifungal agents; will have no age limit; and will be international in scope.

**American Cancer Society Award.** The American Cancer Society sponsors this award to honor outstanding achievements in the fields of epidemiology, biomarkers, and prevention. There are no age or geographical restrictions on the awardee.

**AACR Special Conferences in Cancer Research**

A number of meetings are now being organized in the AACR's series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Non-members may receive this information by sending their names and addresses to: Meetings Mailing List, AACR, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR's website (<http://www.aacr.org/confncr.html>).

October 14-18, 1998

Gene Regulation and Cancer  
(10th Anniversary of AACR Special Conferences in Cancer Research)

Chairpersons:

PHILLIP A. SHARP, Cambridge, MA  
JACQUELINE A. LEES, Cambridge, MA  
STEVEN L. MCKNIGHT, Dallas, TX  
The Homestead, Hot Springs, VA

December 2-6, 1998

New Research Approaches to the Prevention and Cure of Prostate Cancer

Co-Chairpersons:

JONATHAN W. SIMONS, Baltimore, MD  
KENNETH J. PIENIA, Ann Arbor, MI  
Hyatt Grand Champions Resort, Indian Wells  
(Palm Springs), CA

March 1999

Molecular Determinants of Sensitivity to Antitumor Agents

Co-Chairpersons:

MICHAEL B. KASTAN, Memphis, TN  
I. DAVID GOLDMAN, Bronx, NY  
Whistler Resort and Conference Centre, Whistler, B.C., Canada

## AUTHOR INDEX

September 1998

- Abe, T., 2129  
 Agarwal, S., 2147  
 Albert, D. M., 2253  
 Alberts, S. R., 2111  
 Ames, M. M., 2111  
 Anker, G., 2089  
 Aoyagi, K., 2153  
  
 Banerjee, M., 2119  
 Barberi-Heyob, M., 2039  
 Bartlett, J. M. S., 2245  
 Beaman, A., 2119  
 Björk, P., 2079  
 Boag, A. H., 2279  
 Brown, N., 2085  
  
 Caenazzo, C., 2179  
 Champion, L., 2039  
 Camping, B. G., 2279  
 Carson, W. E., 2219  
 Carvalho, M., 2195  
 Celis, E., 2103  
 Cher, M. L., 2119  
 Cheung, N-K. V., 2135  
 Christian, M. C., 2095  
 Chu, E., 2229  
 Cincotta, L., 2207  
 Clayman, G. L., 2265  
 Cole, S. P. C., 2279  
 Colomer, R., 2161  
 Conroy, T., 2039  
 Cortés-Funes, H., 2161  
 Cotter, S. M., 2207  
 Covington, W., 2085  
  
 Danenberg, K. D., 2229  
 Danenberg, P. V., 2229  
 Daniel, R. W., 2103  
 Darjatmoko, S. R., 2253  
 Dearing, M. P., 2095  
 Deeley, R. G., 2279  
 Deo, Y. M., 2237  
 Di Salle, E., 2089  
 Dowsett, M., 2089  
  
 Edman, K., 2079  
 Elias, A., 2027  
 Erlichman, C., 2111  
 Etienne, M-C., 2039  
  
 Fety, R., 2039  
 Fidler, I. J., 2053  
 Foley, J. W., 2207  
 Frank, D. K., 2265  
 Franklin, W. A., 2065  
 Frederick, M. J., 2265  
 Frei, E., III, 2027  
 Frimberger, A. E., 2207  
  
 Gabra, H., 2245  
  
 Garbisa, S., 2179  
 Garcia, F. U., 2153  
 Geisler, J., 2089, 2125  
 Geisler, S. B., 2125  
 Gerald, W. L., 2135  
 Giraldo, A., 2179  
 Goldberg, R. M., 2111  
 Gouni-Berthold, I., 2141  
 Gramsch, C., 2047  
 Gunnarsson, P-O., 2079  
 Gurski, K. J., 2103  
 Guzmán, C., 2161  
  
 Hameed, M., 2135  
 Hardouin, A., 2039  
 Hartley-Asp, B., 2079  
 Haruma, K., 2195  
 Hasuda, S., 2129  
 Hauck, M. L., 2071  
 Hawkins, R. A., 2245  
 Hipfner, D. R., 2279  
 Hirai, T., 2195  
 Ho, D. H., 2085  
 Höllt, V., 2047  
 Hryniuk, W., 2027  
 Hsueh, C-T., 2201  
 Hu, Y., 2153  
 Hukku, B., 2169  
 Huo, Y. Y., 2085  
  
 Iwamoto, Y., 2273  
  
 Johnson, B. E., 2095  
 Ju, J., 2229  
  
 Kajiyama, G., 2195  
 Kakeji, Y., 2129  
 Kane, S. E., 2229  
 Kanetake, H., 2187  
 Kasturi, V. K., 2095  
 Keler, T., 2237  
 Kelley, M. J., 2095  
 Kelsen, D., 2201  
 Killion, J. J., 2053  
 King, N., 2089  
 Kitadai, Y., 2195  
 Klinz, M., 2141  
 Ko, Y., 2141  
 Kohno, K., 2273  
 Koji, T., 2187  
 Kramer, K., 2135  
 Kumar, R., 2053  
 Kuniyasu, H., 2053  
 Kuritani, J., 2085  
 Kushner, B. H., 2135  
 Kuwabara, M., 2195  
 Kuwano, M., 2273  
  
 Langdon, S. P., 2245  
  
 Larson, S. M., 2135  
 Lassere, Y., 2085  
 Lenz, H-J., 2229  
 Lindstrom, M. J., 2253  
 Liu, T-J., 2265  
 Lønning, P. E., 2089, 2125  
  
 Maehara, Y., 2129  
 Marincola, F. M., 2103  
 Matherly, L. H., 2169  
 Mathur, M., 2147  
 Merlin, J-L., 2039  
 Milano, G., 2039  
 Miller, W. R., 2245  
 Montero, S., 2161  
 Moore, A. S., 2207  
 Morton, T. L., 2095  
 Murakami, M., 2103  
  
 Nath, N., 2147  
 Nitti, D., 2179  
  
 Oda, Y., 2273  
 Ohga, T., 2273  
 Ohno, S., 2129  
 Oki, E., 2129  
 Olbricht, S., 2047  
 O'Neil, K., 2095  
 Onisto, M., 2179  
 Ornati, G., 2089  
  
 Park, R. C., 2103  
 Pazdur, R., 2085  
 Perrocheau, G., 2039  
 Piscitelli, S. C., 2095  
 Pontes, E., 2119  
 Powell, I., 2119  
 Pullen, J., 2169  
  
 Rabiaz, G. J., 2245  
 Ralhan, R., 2147  
 Ravindranath, Y., 2169  
 Refsum, H., 2125  
 Reid, J. M., 2111  
 Richardson, P., 2027  
 Richardson, R. L., 2111  
 Ritchie, A. A., 2245  
 Rivière, A., 2039  
 Roessner, A., 2047  
 Rolland, F., 2039  
 Ross, D., 2065  
 Russell, E. K., 2095  
 Russoniello, C., 2237  
  
 Sachinidis, A., 2141  
 Saito, Y., 2187  
 Sakai, H., 2187  
 Sakamoto, A., 2273  
  
 Sartor, L., 2179  
 Scalerta, R., 2179  
 Schlom, J., 2237  
 Schmidt, H., 2047  
 Schmitt, J., 2047  
 Schulz, So., 2047  
 Schulz, St., 2047  
 Schwartz, G. K., 2201  
 Sette, A., 2103  
 Shah, K. V., 2103  
 Shima, I., 2153  
 Shinohara, H., 2053  
 Shinohara, N., 2273  
 Shukla, N. K., 2147  
 Siegel, D., 2065  
 Sladek, G. G., 2095  
 Sloan, J. A., 2111  
 Smaaland, R., 2125  
 Smyth, J. F., 2245  
 Somasundaram, C., 2237  
 Stearns, M. E., 2153, 2257  
 Steller, M. A., 2103  
 Sugimachi, K., 2129  
 Sumii, K., 2195  
  
 Tahara, E., 2195  
 Tanaka, S., 2195  
 Taub, J. W., 2169  
 Tesdale, A. L., 2245  
 Tokutomi, T., 2195  
 Totzke, G., 2141  
 Trimble, E. L., 2103  
 Tsuneyoshi, M., 2273  
 Tsurusaki, T., 2187  
 Turner, G. A., 2095  
 Tveit, K. M., 2125  
  
 Uchiumi, T., 2273  
 Ueland, P. M., 2125  
  
 Valdimarsson, G., 2279  
 Vetter, H., 2141  
  
 Walz, P. H., 2079  
 Wang, M., 2153, 2257  
 Wasylyk, B., 2147  
 Weise, W., 2047  
 Wheeler, C., 2027  
 Wiborny, D., 2047  
 Wilkerson, C. L., 2253  
 Williamson, M., 2169  
 Wong, S. C., 2169  
 Wood, D. P., Jr., 2119  
 Wright, S. R., 2279  
  
 Yoshida, K., 2195  
  
 Zalutsky, M. R., 2071  
 Zhang, L., 2169

# Instructions for Authors

## Scope

*Clinical Cancer Research*, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. *Clinical Cancer Research* is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

## Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in *Clinical Cancer Research*, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for \$5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator's Institutional Review Board.

## Review Process

The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

## Publication Fees

A page charge of \$50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

## Procedures for Submission

Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal's Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. **For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.**

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in *Clinical Cancer Research* that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

## Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;
9. Figures.

## References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

**SAMPLE REFERENCES:**

1. Shaffer, D. W., Smith, L. S., Burris, H. A., Clark, G. M., Eckardt, J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. *Cancer Res.*, 53: 5929-5933, 1993.
2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal antibody therapy of cancer. *In*: H. M. Pinedo, B. A. Chabner, and D. L. Longo (eds.), *Cancer Chemotherapy and Biological Response Modifiers Annual*, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers B.V., 1990.

**Figures**

Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is \$975 per color figure. Submit color figures on flexible backing.

**Proofs**

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. **Proofs not received by the deadline will be published without the authors' corrections.** Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

**Typesetting Manuscripts from Computer Disks**

*Clinical Cancer Research* requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

**Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors**

John Mendelsohn, M.D., Editor-in-Chief  
Department of Educational Publishing Services-227  
The University of Texas M. D. Anderson Cancer Center  
1515 Holcombe Boulevard  
Houston, TX 77030  
Phone: (713) 792-6014; Fax: (713) 792-6016  
E-mail: jmendelsohn@notes.mdacc.tmc.edu

*Growth factors, hormones, cell growth; radiation therapy, surgery, subspecialty investigation*

Waun Ki Hong, M.D., Deputy Editor  
Department of Thoracic/Head & Neck Medical Oncology  
The University of Texas M. D. Anderson Cancer Center  
Box 80  
1515 Holcombe Boulevard  
Houston, TX 77030  
Phone: (713) 792-6363; Fax: (713) 796-8655  
E-mail: waun-hong@isqm.mda.uth.tmc.edu

*Clinical trials targeted at specific malignancies, chemoprevention*

Bruce A. Chabner, M.D.  
Department of Hematology/Oncology  
Massachusetts General Hospital  
Cox Building, Room 640  
100 Blossom Street

Boston, MA 02114  
Phone: (617) 724-3200; Fax: (617) 724-3166  
E-mail: chabner.bruce@mgh.harvard.edu

*Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions*

Michael B. Kastan, M.D., Ph.D.  
Department of Hematology-Oncology  
St. Jude Children's Research Hospital  
332 N. Lauderdale St.  
Memphis, TN 38105-2794  
Phone: (901) 495-3968; Fax: (901) 495-3966  
E-mail: michael.kastan@stjude.org

*Cell cycle regulation, cell death*

Lance A. Liotta, M.D., Ph.D.  
Laboratory of Pathology  
National Cancer Institute  
Building 10, Room 2A33  
National Institutes of Health  
10 Center Drive, MSC 1500  
Bethesda, MD 20892-1500  
Phone: (301) 496-3185; Fax: (301) 402-0043  
E-mail: lance@helix.nih.gov

*Pathology, metastasis*

David Sidransky, M.D.  
Otolaryngology/Head & Neck Cancer Research  
Johns Hopkins University  
818 Ross Research Building  
720 Rutland Avenue  
Baltimore, MD 21205-2196  
Phone: (410) 550-5153; Fax: (410) 614-1411  
E-mail: dsidrans@welchlink.welch.jhu.edu

*Molecular pathogenesis, molecular correlates*

Paul Sondel, M.D., Ph.D.  
Departments of Pediatrics, Human Oncology, & Genetics  
University of Wisconsin Clinical Science Center  
K4/448  
600 Highland Avenue  
Madison, WI 53792  
Phone: (608) 263-9069; Fax: (608) 263-4226  
E-mail: pmsondel@facstaff.wisc.edu

*Immunotherapy and cytokines—preclinical, and clinical trials*

Beverly A. Teicher, Ph.D.  
Lilly Research Laboratories  
Lilly Corporate Center, DC 0540  
Indianapolis, IN 46285  
Phone: (317) 276-2739; Fax: (317) 277-3652  
E-mail: teicher-beverly-a@lilly.com

*Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models*

Jeffrey M. Trent, Ph.D.  
Laboratory of Cancer Genetics  
National Center for Human Genome Research  
National Institutes of Health  
Building 49, Room 4A22  
49 Convent Drive, MSC 4470  
Bethesda, MD 20892-4470  
Phone: (301) 402-2023; Fax: (301) 402-2040  
E-mail: jtrent@nchgr.nih.gov

*Genetics, cytogenetics*

**For more information, contact:**

John Mendelsohn, M.D., Editor-in-Chief, *Clinical Cancer Research*, Department of Educational Publishing Services-227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6014; Fax: (713) 792-6016

or:

Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Phone: (215) 440-9300; Fax: (215) 440-9355.



# AMERICAN ASSOCIATION FOR CANCER RESEARCH

## GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

### BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association's high-quality journals *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates;
3. an advance copy of the Program and *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,500 member researchers in the cancer field;
11. the professional benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

### QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

### PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all

members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application in AACR Office	Notification of Candidate
January 1	March
May 1	July
September 1	November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. —OR— The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). —OR— The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department  
American Association for Cancer Research  
Public Ledger Building, Suite 826  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
Phone: 215/440-9300  
FAX: 215/440-9412  
E-mail: aacr@aacr.org

### RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1998 annual dues for active members are \$175, \$100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$100 in 1998) and may, if they wish, subscribe to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.  
Executive Director

# AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building • Suite 826 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483

## APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: \_\_\_\_\_ DATE OF BIRTH: \_\_\_\_\_  
LAST FIRST M.I. Month/Day/Year

PRESENT POSITION/TITLE: \_\_\_\_\_

INSTITUTIONAL AFFILIATION: \_\_\_\_\_

INSTITUTIONAL ADDRESS: \_\_\_\_\_

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: \_\_\_\_\_ FAX NUMBER: \_\_\_\_\_

E-MAIL ADDRESS: \_\_\_\_\_

### PRIMARY FIELD OF RESEARCH (Please check only one):

\_\_\_\_ Biochemistry and Biophysics      \_\_\_\_ Biostatistics      \_\_\_\_ Carcinogenesis  
\_\_\_\_ Cellular Biology and Genetics      \_\_\_\_ Clinical Investigations      \_\_\_\_ Endocrinology  
\_\_\_\_ Epidemiology      \_\_\_\_ Immunology      \_\_\_\_ Molecular Biology and Genetics  
\_\_\_\_ Preclinical Pharmacology and      \_\_\_\_ Virology      \_\_\_\_ Other: \_\_\_\_\_  
Experimental Therapeutics (Please specify)

### ACADEMIC DEGREES (Including where and when granted)

\_\_\_\_\_  
\_\_\_\_\_

### EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

\_\_\_\_\_  
\_\_\_\_\_

**PUBLICATIONS** (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

CANDIDATE IS APPLYING FOR (Check one):     ACTIVE     CORRESPONDING    MEMBERSHIP

CANDIDATE NOMINATED BY\*: \_\_\_\_\_ (Please print)  
CANDIDATE SECONDED BY\*: \_\_\_\_\_ (Please print)

### STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

Signature of Nominator\* \_\_\_\_\_ Date \_\_\_\_\_ Signature of Seconder\* \_\_\_\_\_ Date \_\_\_\_\_

See Guidelines for Application on the reverse side of this form for further instructions.

\*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR in good standing.



# AMERICAN ASSOCIATION FOR CANCER RESEARCH

## GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

### QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

### BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. optional subscriptions to the Association's high-quality journals: *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. the privilege of electing an Associate Member Council that organizes programs benefiting associate members and that presents their concerns to the AACR Board of Directors;
5. the opportunity to stand for election to the Associate Member Council;
6. preferred access to the AACR Employment Register;
7. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
8. substantially reduced registration rates at special conferences;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
10. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
11. the facilitation of informal scientific exchange with leading researchers in the cancer field.

### PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the

AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1998 are \$55 for associate members residing in the Americas and \$65 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department  
American Association for Cancer Research  
Public Ledger Building, Suite 826  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
Phone: 215/440-9300  
Fax: 215/440-9412  
E-mail: aacr@aacr.org

### RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1998 have been set at \$55 per year for residents of the Americas and \$65 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1998 for the forthcoming annual meeting must have paid dues for 1998. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1998 may retain associate membership until December 31, 2002. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.  
Executive Director



## Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite Microsoft Word (DOS, Windows, and Macintosh)	WordPerfect (DOS, Windows, and Macintosh) XyWrite (DOS and Windows)
---	---

Also acceptable:

Ability AmiPro A <sub>m</sub> S-TeX Appleworks ArborTeX ArborText ClarisWorks WP CPT 8000 CTOS Diablo DisplayWrite Duet Einstein Enable EXP Final Word FullWrite GemWord Plus IBM Writing Assistant Interleaf LaTeX Latex Leading Edge Lotus Manuscript Lotus Write	Mass 11 MS Windows Write MS Works MS Works WP Mac Multimate Multimate Advantage Nibia Nisus (to ASCII file) Notewriter Obun OfficeWriter PC Write PFS First Choice Professional Write Q&A Write Quark XPress RagTime MS Works (to ASCII file) Rich Text Format RSG (to ASCII file) Signature SLITeX SmartWhere SmartWrite II	SoloWriter Sprint Stx SunWrite Symphony TEX TeX78 Text EXecutive Textures Total Word Troff μTeX Volkswriter VuWriter Wang OIS Wang WPS Wang Writer Window Works Windows Write WiziWord Wordstar Wordstar 2000 WriteNow Xerox
---	---	---

Software packages that we are unable to translate:

FrameMaker PageMaker	Ready, Set, Go Scientific Writer
-------------------------	-------------------------------------

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK.  
DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.



## DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

### File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

**Name used to access paper on disk:** \_\_\_\_\_

**Name of computer used (e.g., IBM/PS2):** \_\_\_\_\_

**Operating system and version (e.g., DOS 3.3):** \_\_\_\_\_

**Word processing program and version (e.g., WordPerfect 5.0):** \_\_\_\_\_

[See reverse for acceptable programs.]

**Manuscript number:** \_\_\_\_\_

**First author:** \_\_\_\_\_

**Corresponding author (if different from first author):** \_\_\_\_\_

**Telephone/FAX numbers:** \_\_\_\_\_

This form (both sides) may be reproduced.

# Your Link to the Latest Treatment Strategies



Published by the  
American Association  
for Cancer Research

## *Clinical Cancer Research:* Your source for:

- **Reports of clinical trials**  
Descriptions of the latest treatment strategies being employed worldwide
- **Translational studies**  
Critical research bridging the lab and the clinic
- **Minireviews**  
Concise, informative summaries of broad areas of oncology
- **Meeting reports, and more**  
Reports from scientific meetings, plus special lectures, letters to the editor, and more

### **Editor-in-Chief:**

John Mendelsohn, M.D.  
UT M.D. Anderson Cancer Center



## SUBSCRIBE TODAY!

Call 1-800-633-4931 or (205) 995-1567 or return the coupon below.

### **Yes! I'd like to subscribe!**

**Clinical Cancer Research**  
Vol. 4, 1998, 12 issues, ISSN 1078-0432

#### **AACR Members:**

Contact AACR for special subscription rates

#### **Individual** (For individual use only; not for use in a library)

- \$120
- \$ 40 should be added for delivery outside the U.S.

#### **Institutional** (Available only as a combined subscription with *Cancer Research*)

- \$795
- \$130 should be added for delivery outside the U.S.

Canada: Add 7% GST; MD: Add State Sales Tax

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Postal Code \_\_\_\_\_

Country \_\_\_\_\_

#### **Method of Payment**

- Enclosed check or money order in U.S. dollars drawn on U.S. bank. Payable to American Association for Cancer Research.
- Institutional purchase order # \_\_\_\_\_ is enclosed.
- Please charge my  MasterCard  VISA  American Express

Account Name \_\_\_\_\_

Account Number \_\_\_\_\_

Expiration Date \_\_\_\_\_

Signature \_\_\_\_\_

#### **Mail coupon to:**

*Clinical Cancer Research*, Subscription Office,  
P.O. Box 11806, Birmingham, AL 35202, USA.  
If paying by credit card, fax form to: (205) 995-1588.

# The way to silence a killer is to make some noise.



Cancer kills more than 1,500 people every day. And it is the leading cause of death by disease in our children. Yet, for every ten dollars in taxes the government collects, it spends only *one penny* on cancer research. We can do better. For the more than eight million Americans now living with cancer - and for the millions more at risk - we must do better. THE MARCH is a momentous event uniting people in Washington, DC, and in communities across the nation. We are coming together to make cancer the nation's # 1 research priority. We are raising our voices to say No more... No more suffering... No more excuses... No more cancer. Please join us.

THE  
MARCH  
Coming Together To Conquer Cancer<sup>SM</sup>  
September 25 & 26, 1998

1730 K Street, 4th Floor  
Washington, DC 20006  
1.877.THE.MARCH  
[www.themarch.org](http://www.themarch.org)

**THE SIDNEY KIMMEL FOUNDATION *for* CANCER RESEARCH**

*The AACR is a proud supporter of The March. For information about AACR members' March-related activities, please call the AACR Office at (215) 440-9300.*